Clinerion gets new digs as part of expansion, continues to add staff

Basel, Switzerland
Clinerion's new offices are almost double the size of its previous location in Basel. (Getty Images/Xantana)

Swiss clinical trial patient recruitment specialist Clinerion is moving to new digs in its home base of Basel as its expansion continues and it ramps up employment.

The company said that it has been ramping up staffing in the last half of 2018 across all areas of the organization. 

The new offices are almost double the size of its previous location in Basel, which is considered a one of the pharmaceutical industry’s global hubs. Clinerion said that location is key for its analysts to tap into valuable insights from anonymized patient data throughout its network of hospital and data partners.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Basel has critical mass in its life sciences ecosystem and an infrastructure which promotes a strong innovation culture,” Ian Rentsch, Clinerion’s chief executive, said in a statement. “Here, we have the opportunity to interact with leaders of the industry on a close, daily basis.”

Clinerion has been on a network expansion spree and has said it plans to reach every continent and almost double the number of accessible patients to 310 million by the end of the year. The company uses electronic health records from a large global network of hospitals it maintains to help trial sponsors identify patients, as well as generate real-world evidence and market access analysis.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.